BioPharmSignal logoBioPharmSignal

Biotech News

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights

SAB Biotherapeutics (SABS)SAB BiotherapeuticsEarnings

Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast Track designation for SAB-142 in new-onset Stage 3 T1D Operational runway through

Related news

SABSSAB Biotherapeutics2026-10-29 12:30 EST

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-10-13 12:30 EST

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

ZURAZura Bio2026-10-27 11:30 EST

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

AVTXAvalo Therapeutics2026-11-05 12:00 EST

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ANABAnaptysBio, Inc.2026-09-21 20:15 EST

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-11-05 12:30 EST

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

BMYBMYBristol-Myers Squibb Company2026-10-29 10:59 EST

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

MLTXMoonLake Immunotherapeutics2026-11-04 12:00 EST

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

View all latest news

SAB Biotherapeutics

Fully Human Polyclonal Antibodies SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies. SAB-142 SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes. SAFEGUARD The registrational...

Recent company news

SABSSAB Biotherapeutics2026-11-05 12:30 EST

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights

SABSSAB Biotherapeutics2026-10-29 12:30 EST

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-10-14 12:30 EST

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

SABSSAB Biotherapeutics2026-10-13 12:30 EST

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-10-01 12:30 EST

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Stock data

Close
2.94 USD
Market cap
266.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States